Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.72 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | KHK | P50053 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17311103 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKHPGD | |
| Hydrochloric Acid SCHEMBL3333683 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKHPGD | |
| Hydrochloric Acid SCHEMBL3335525 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKHPGD | |
| Hydrochloric Acid SCHEMBL1736189 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKHPGD | |
| Hydrochloric Acid SCHEMBL1814485 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKHPGD | |
| Hydrochloric Acid SCHEMBL1094729 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL16633376 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1094728 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL238942 | 0.98 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL1447785 | 0.98 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008790-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20240293410-A1 | COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4360707-A2 | COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-11938136-B2 | Compositions for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3373972-B1 | COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | disclosed |
| US-20240076302-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4241772-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2023-09-13 | — | — | EP | disclosed |
| EP-3663296-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | disclosed |
| CN-108289959-B | Composition for treating spinal muscular atrophy | 豪夫迈·罗氏有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3374362-A1 | COMPOUNDS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | H. Hoffnabb-La Roche Ag (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180237472-A1 | C-3 NOVEL TRITERPENONE WITH C-28 AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| US-9969754-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170197990-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2017081111-A1 | COMPOUNDS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017080967-A1 | COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| EP-3143025-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173181-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008790-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM22, RBM17 | HTR6 3128/4885L3MBTL3 1103/4885L3MBTL1 1055/4885 |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HTR6 39/4885L3MBTL3 2875/4885L3MBTL1 4246/4885 |
| US-20180237472-A1 | C-3 NOVEL TRITERPENONE WITH C-28 AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, GTF3C3 | HTR6 4454/4885L3MBTL3 1400/4885L3MBTL1 2147/4885 |
| US-20170197990-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTR6 3502/4885L3MBTL3 3589/4885L3MBTL1 3095/4885 |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | HTR6 3502/4885L3MBTL3 3589/4885L3MBTL1 3095/4885 |
| US-20240076302-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTR6 3502/4885L3MBTL3 3589/4885L3MBTL1 3095/4885 |
| US-11938136-B2 | Compositions for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, PYGM | HTR6 3599/4885L3MBTL3 3943/4885L3MBTL1 3367/4885 |
| US-20240293410-A1 | COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | HTR6 3599/4885L3MBTL3 3943/4885L3MBTL1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.